SFM
GLMD icon

Sphera Funds Management’s Galmed Pharmaceuticals GLMD Stock Holding History

Sphera Funds Management’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,323
Closed -$2.16M – 122
2017
Q4 		$2.16M Buy
+1,323
New +$1.95M 0.25% 93
2014
Q3 		– Sell
-944
Closed -$1.66M – 134
2014
Q2 		$1.66M Hold
944
– – 0.41% 58
2014
Q1 		$1.95M Buy
+944
New +$2.21M 0.45% 48

Other funds holding GLMD

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sphera Funds Management's GLMD Position: Q1 2018 in Review

Sphera Funds Management sold out of Galmed Pharmaceuticals (GLMD) in Q1 2018, closing a stake of 1,323 shares — an estimated $2.16M sold.

Sphera Funds Management first reported a position in GLMD in Q1 2014 and held it in 3 quarters. The position peaked at $2.16M in Q4 2017. 19 funds tracked by Wall St. Rank hold GLMD as of Q1 2018.

  • Sphera Funds Management reported no remaining Galmed Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Sphera Funds Management sold 1,323 Galmed Pharmaceuticals shares in Q1 2018, an estimated $2.16M.
  • Sphera Funds Management first reported a position in Galmed Pharmaceuticals in Q1 2014 and held it in 3 quarters.
  • Sphera Funds Management's Galmed Pharmaceuticals position peaked at $2.16M in Q4 2017.
  • 19 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2018.

Based on Sphera Funds Management's 13F filing for Q1 2018, filed 10 May 2018.